PROSION Therapeutics, a pharmaceutical startup founded in 2020, is committed to addressing unmet medical needs through innovation in drug development. Their proprietary platform aims to unlock undruggables, focusing on diseases such as cancer and diabetes. Most recently, the company received a Seed Round investment on 01 May 2022 from Freigeist Capital. With this support, PROSION is poised to continue its groundbreaking work in revolutionizing drug development to benefit patients and healthcare providers worldwide.
PROSION
Addressing unmet medical needs through innovation in drug development
Founded 2020
2-10 employees
Seed
Total: $2.46M
Pharmaceutical
General Information
Get notified when PROSION moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track PROSION
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Pharmaceutical
About PROSION
Taxonomy: drug development, innovation, unmet medical needs, proprietary platform, cancer, diabetes, undruggables
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | •••••• | 1 | •••• •••• | 01 May 2022 |
| Grant | •••••• | 1 |
|
16 Jun 2021 |
FAQ About PROSION
Addressing unmet medical needs through innovation in drug development
PROSION was founded in 2020.
PROSION operates in the following industries: Pharmaceutical.
PROSION has approximately 2-10 employees.
PROSION has completed 2 funding rounds, raising a total of $2.46M. The latest funding stage is Seed.
We're actively collecting intelligence on PROSION.
Track PROSION to get notifiedDon't just browse. Track.
Signal Tracker monitors PROSION and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.